louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02828072: Sudarshan Kriya Yoga and Cardiac Autonomic Control in Patients With Anxiety-Depression Disorders
Official title: Effects of Sudarshan Kriya Yoga on Cardiac Autonomic Control and Anxiety/Depression Levels in Patients Affected by Anxiety-Depression Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Depression
Lead sponsor: University of Milan
Sponsor class: OTHER
First posted: 2016-07-11
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effects of Sudarshan Kriya Yoga (SKY) on autonomic function in patients with anxiety-depression disorders is unknown. Thus, the authors will investigate cardiac autonomic control in a population of patients with anxiety-depression disorders which will undergo a specific SKY treatment.

Detailed description: Several studies have demonstrated that adjuvant therapies as exercise and breathing training are effective in improving cardiac autonomic control (CAC) in patients with affective spectrum disorders. However, the effects of Sudarshan Kriya Yoga (SKY) on autonomic function in this population is unknown. To test the hypothesis that SKY training improves CAC, cardiorespiratory coupling and adaptive response of sympatho-vagal balance to orthostatic changes were evaluated in patients with anxiety and/or depression disorders.

The authors will enroll patients with a diagnosis of anxiety and/or depression disorders (DSM-IV) and they will divide them in two groups: 1) conventional therapy (Control) and 2) conventional therapy associated with SKY (Treatment) for 15 days. Anxiety and depression levels will be determined using quantitative questionnaires. For the assessment of CAC and cardiorespiratory coupling, cardiorespiratory traces will be analyzed using monovariate and bivariate autoregressive spectral analysis, respectively.

Eligibility criteria: Inclusion Criteria:

* diagnosis of anxiety-depression disorder

Exclusion Criteria:

* absence of sinus rhythm on ECG
* absence of any cardiovascular and metabolic disorder

Primary outcomes:
measure: Changes in autonomic control
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Toschi-Dias E, Tobaldini E, Solbiati M, Costantino G, Sanlorenzo R, Doria S, Irtelli F, Mencacci C, Montano N. Sudarshan Kriya Yoga improves cardiac autonomic control in patients with anxiety-depression disorders. J Affect Disord. 2017 May;214:74-80. doi: 10.1016/j.jad.2017.03.017. Epub 2017 Mar 7.
Clinical trial NCT00228072: Liposuction as Treatment for Excessive Axillary Sweat
Official title: Suction-Curettage vs. Standard Excision in Axillary Hyperhidrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hyperhidrosis
Keywords: Hyperhidrosis
Axillary
Excision
Suction-curettage
Outcome
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2005-09-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if suction-curettage of the axilla is favorable in regard to effect, recovery and cosmetic appearance compared to standard surgical excision of the skin of the axilla in case of excessive sweating.

Detailed description: The surgical standard treatment for isolated excessive axillary sweating is excision of the hair-bearing area of the axilla. This technique is associated with a risk of impaired wound healing, infections, wide scars and a risk of impairment in the movement of the arm (seldom).

A new technique suction-curettage, much alike the liposuction technique, in which the dermis is curettage from a sub-dermal approach with a cutting and sucking devise, may be promising in regard to recovery and cosmetic appearance postoperatively, but the effect of the sweat production is not well known. This study compares liposuction vs. standard excision in individuals with isolated excessive isolated axillary sweating randomized to treatment with one of each technique in both axillas.

Eligibility criteria: Inclusion Criteria:

* Adult individuals with primary axillary hyperhidrosis

Exclusion Criteria:

* Secondary axillary hyperhidrosis
* Hidrosadenitis axillaris/inguinalis
* Prior surgery
* Iontophoresis or botox treatment 12 months prior
* Known hypersensitivity to local analgetics (lidocaine)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Department of Plastic Surgery, Odense University Hospital
state: Fyn
Study officials:
affiliation: University Center of Wound Healing, Dept. of Plastic Surgery, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark
name: Finn Gottrup, DMsci
role: STUDY_CHAIR
affiliation: Department of Plastic Surgery, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark
name: Torben Moeller-Christensen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03591172: Using Three Different Final Irrigants and Showing Their Effects on the Success of Revascularization
Official title: Assessment of Implementing Nano-technology in the Irrigation Protocol of One Step Revascularization For Necrotic Mature Teeth
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Post-operative Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-07-19
Enrollment: 75
Sex: ALL
Minimum age (years): 15
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: this study will assess different irrigating materials on the success revascularization of necrotic mature teeth associated with PRF.

Detailed description: Nano-propolis and Propolis will be used as final endodontic irrigants and will be compared to saline in Revascularization of necrotic mature teeth.

Eligibility criteria: Inclusion Criteria:

* mature teeth.
* teeth with periapical periodontitis.
* Maxillary anterior teeth
* Patients should be free from any systemic disease
* Patients who will agree to the consent and will commit to follow-up period.

Exclusion Criteria:

* Patients with immature roots.
* Patients with any systemic disease that may affect normal healing.
* Patients with swelling. .Pregnant females. .Patients who could/would not participate in a 1-year follow-up. .Patients with fistula. .Patients with old age. .Teeth with periodontal involvement. .Teeth with vertical root fractures. .Non-restorable teeth.

Primary outcomes:
measure: post-operative pain: Visual analogue scale
timeFrame: 1 year
Secondary outcomes:
measure: periapical healing
timeFrame: 1 year
measure: sensitivity
timeFrame: 1 year
measure: survival
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05071872: PMCF of Rotarex®S & Aspirex®S Catheters in Treating Thrombotic Occlusion of Arteriovenous Graft
Official title: Retrospective Post-Market Clinical Follow Up of Rotarex®S & Aspirex®S Catheters in Treating Thrombotic Occlusion of Arteriovenous Graft for Dialysis Access (Artificial Bypass)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arteriovenous Graft Thrombosis
Lead sponsor: Straub Medical AG
Sponsor class: INDUSTRY
First posted: 2021-10-08
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute thrombotic occlusion of arteriovenous graft for dialysis access (Artificial Bypass) treated with either Rotarex®S Catheter nor Aspirex®S Catheter

Brief summary: Retrospective Post-Market Clinical Follow Up of Rotarex®S \& Aspirex®S Catheters in treating thrombotic occlusion of Arteriovenous Graft for dialysis access (Artificial Bypass)

Detailed description: To evaluate the safety, technical performance, and clinical efficacy of the Rotarex®S \& Aspirex®S Catheters as a stand-alone and adjunctive therapy for the treatment of acute thrombotic occlusion of arteriovenous graft for dialysis access (Artificial Bypass) in accordance with Rotarex®S \& Aspirex®S Catheters intended use.

Eligibility criteria: Inclusion Criteria:

1. Female or male subject with a minimum age of 18 years
2. Treatment performed between 2013 and 2020
3. Occlusion in arteriovenous graft
4. For the Rotarex®S group: use of Rotarex®S Catheter
5. For the Aspirex®S group: use of Aspirex®S Catheter

Exclusion Criteria:

1. Subjects not appropriate for this study according to the opinion of the principal investigator

Primary outcomes:
measure: Technical success
timeFrame: Day 1
Secondary outcomes:
measure: Procedural success
timeFrame: Day 1
measure: Successful use of AV-Graft as dialysis access
timeFrame: Up to 14 days
measure: Primary and Secondary Patency
timeFrame: 10 days, 1, 3 and 6 months
measure: (SAEs) Serious Adverse events Rate
timeFrame: 6 months
measure: Procedure-related Adverse events Rate
timeFrame: 6 months
measure: (ADEs) Adverse device effects Rate
timeFrame: 6 months
measure: (SADEs) Serious Adverse Device Effects Rate
timeFrame: 6 months
Other outcomes:
Locations:
city: Příbram
country: Czechia
facility: Angiocentrum Příbram
Study officials:
affiliation: Angiocentrum Příbram
name: Samuel Heller, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03182972: Intervention Study on Medication Reconciliation Among Pharmacists in Two Tertiary Hospitals in Nigeria
Official title: Intervention Study on Medication Reconciliation Among Pharmacists in Two Tertiary Hospitals in Nigeria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intervention Study
Keywords: intervention study
medication reconciliation
pharmacists
Nigeria
Diabetes
Hypertension
Lead sponsor: University of Ibadan
Sponsor class: OTHER
First posted: 2017-06-09
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: University College Hospital, Ibadan will serve as the intervention group while University of Ilorin Teaching Hospital, Ilorin will serve as the control group.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will assess the current practice of medication reconciliation among pharmacists in the selected institutions with a view to making an intervention to address gaps discovered

Detailed description: Background information garnering will be done among the pharmacists in the two selected hospitals to collect data on current practice of medication reconciliation. Focus group discussion will be done in the intervention group so as to identify peculiarities of their practice and to provide the best approach to carrying out the intervention. Diabetes and hypertensive patients in medical outpatient clinic will be interviewed in order to assess current practice of medication reconciliation.

Intervention will be channeled towards addressing gaps discovered. University College Hospital, Ibadan, Oyo State will be the intervention group, while University of Ilorin Teaching Hospital, Kwara State will be the control group.

The effect of the intervention will be measured over time to ensure that medication reconciliation is implemented in the selected institutions.

Eligibility criteria: Inclusion Criteria:

* Participant has diabetes and/or hypertension
* Registered pharmacists in the selected institutions

Exclusion Criteria:

* Participants that are neither diabetic nor hypertensive
* Unregistered pharmacists in the selected institutions

Primary outcomes:
measure: Medication reconciliation: Percentage unreconciled medications
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ilorin
country: Nigeria
facility: University of Ilorin Teaching Hospital
state: Kwara
city: Ibadan
country: Nigeria
facility: University College Hospital
state: Oyo
Study officials:
affiliation: University of Ibadan
name: TITILAYO O FAKEYE, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06504472: A Randomized Triple-Blind Placebo-Controlled Study to Evaluate the Effects of a Supplement on Lower Urinary Tract Symptoms in Men.
Official title: A Randomized Triple-Blind Placebo-Controlled Study to Evaluate the Effects of a Supplement on Lower Urinary Tract Symptoms in Men.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lower Urinary Tract Symptoms
Benign Prostatic Hyperplasia
Erectile Dysfunction
Keywords: Pumpkin Seed Extract
Lycopene
Stinging Nettle
Beta-Sitosterols
Lead sponsor: Optimale
Sponsor class: INDUSTRY
Collaborators: name: Citruslabs
First posted: 2024-07-16
Enrollment: 80
Sex: MALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the effects of the ProstaThrive™ supplement on lower urinary tract symptoms (LUTS) in men. It is a 90-day virtual, randomized, placebo-controlled trial with 80 male participants aged 40 and above. The primary endpoint is the reduction in LUTS, while secondary endpoints include changes in sexual function and performance.

Detailed description: This is a virtual two-arm randomized placebo-controlled clinical trial lasting 90 days. Participants will take the ProstaThrive™ supplement or a placebo daily and complete questionnaires at Baseline, Day 30, Day 60, and Day 90. The study will assess the efficacy of ProstaThrive™ on LUTS such as urinary urgency, nighttime urination frequency, perceived urinary flow, and bladder emptying, as well as secondary outcomes related to sexual function.

Eligibility criteria: Inclusion Criteria:

* Male participants aged 40+
* Experience symptoms such as frequent nighttime urination, incomplete bladder emptying, weak urinary stream, and frequent daytime urination
* Difficulty in getting or maintaining an erection
* Willing to avoid introducing any new products or medications targeting LUTS or erectile dysfunction during the study period

Exclusion Criteria:

* Recent surgeries or invasive treatments
* History of prostate or male reproductive cancers
* Urinary issues caused by neurological conditions
* Previous surgery on the genitals, prostate, bladder, or urethra
* Known allergies to product ingredients
* Diagnosed with chronic health conditions impacting study participation
* Current substance abuse
* Participation in other clinical trials
* Taking medications or supplements targeting LUTS or erectile dysfunction

Primary outcomes:
measure: Change in Lower Urinary Tract Symptoms (LUTS)
timeFrame: Baseline, Day 30, Day 60, and Day 90
Secondary outcomes:
measure: Change in Sexual Function and Performance
timeFrame: Baseline, Day 30, Day 60, and Day 90
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Citruslabs
state: California
Study officials:
References:
Clinical trial NCT05907772: Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma
Official title: Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma: A Multi-center Retrospective Cohort Study in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer of Liver
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2023-06-18
Enrollment: 522
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 522 HCC patients underwent liver transplant with pre-operative PIVKA-II records were studied.

Brief summary: This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.


Eligibility criteria: Inclusion Criteria:

* The HCC patients received LT with pre-operative PIVKA-II records performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.

Exclusion Criteria:

* (1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up or incomplete important parameters records.

Primary outcomes:
measure: Overall survival
timeFrame: January 2015 to December 2020
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT06354972: Impact of SASP in the GCF on the Outcomes of Periodontal Regeneration
Official title: Impact of the Senescence Associated Secretory Phenotype in the Gingival Crevicular Fluid on the Outcomes of Periodontal Regeneration
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontal Diseases
Lead sponsor: University of Turin, Italy
Sponsor class: OTHER
First posted: 2024-04-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients with a diagnosis of stage III or IV periodontitis who had undergone steps I-II of periodontal therapy were considered for inclusion.

Brief summary: Objectives: To test the impact of clinical inflammation and molecular expression profile (senescence-associated secretory phenotype; SASP) in the gingival crevicular fluid (GCF) on the outcomes of minimally-invasive periodontal regeneration in intra-bony defects.

Methods: Sites associated with intrabony defects ≥ 3 mm requiring periodontal regeneration through minimally-invasive surgical technique were included. Pre-operatively, GCF was sampled for inflammatory biomarker analysis related to SASP \[interleukin (IL)-1β, IL-6 and IL-12; matrix-metalloproteinases (MMP)-8 and -9\]. Correlation analyses and logistic regression models were performed to assess the impact of predictors on clinical and radiographic outcomes.


Eligibility criteria: Inclusion criteria comprised:

1) diagnosis of stage III or IV periodontitis (Papapanou et al. 2018b); 2) full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) of \<15%; 3) completion of steps I-II of periodontal treatment at least 2 months priorly; 4) tooth with residual PPD ≥ 6 mm, BoP+, and a radiographic intrabony component ≥ 3 mm, lacking furcation involvement (Aimetti et al. 2023), considered suitable for a minimally invasive procedure (Cortellini and Tonetti 2007) (Fig. 1A).

Exclusion criteria encompassed:

1) age \< 18 years; 2) current smokers; 3) contraindications to surgery; 4) systemic diseases that could impact periodontal healing; 5) pregnancy and lactation; 6) a history of periodontal surgery at the experimental teeth.

Primary outcomes:
measure: Clinical attachment level change
timeFrame: [Time Frame: 12 months]
measure: Achievement of composite outcome measure
timeFrame: [Time Frame: 12 months]
Secondary outcomes:
measure: Radiographic bone level change
timeFrame: [Time Frame: 12 months]
measure: Probing pocket depth change
timeFrame: [Time Frame: 12 months]
Other outcomes:
Locations:
city: Turin
country: Italy
facility: CIR Dental School
Study officials:
References:
Clinical trial NCT06027372: Heart Rate Variability and Nocturnal Blood Oxygen Saturation in Patients With Idiopathic Pulmonary Fibrosis
Official title: Differences in Heart Rate Variability and Nocturnal Blood Oxygen Saturation of Patients With Idiopathic Pulmonary Fibrosis Between at Baseline and During Acute Exacerbation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Idiopathic Pulmonary Fibrosis
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2023-09-07
Enrollment: 70
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: individuals meet the diagnosis of idiopathic pulmonary fibrosis

Brief summary: The goal of this observational study is to compare the overnight heart rate variability (HRV) and nocturnal oxygen saturation (SpO2) in patients with idiopathic pulmonary fibrosis (IPF). The main questions it aims to answer are: (1). if there are correlations between pulmonary function test and HRV and overnight SpO2; (2). if HRV and SpO2 can predict the occurrence of acute exacerbation in patients with IPF. Participants will be asked to examine pulmonary function test (including lung volumes and six-minute walk test) and wear pulse oxygenation recorder and "LARGAN" ECG Holter" ("LARGAN HEALTH TECHNOLOGY" Sleep Apnea And Sleep Quality Examination System) during sleep.


Eligibility criteria: Inclusion Criteria:

* individuals meet the diagnosis of idiopathic pulmonary fibrosis
* individuals agree to participate this study and sign the informed consent
* individuals have cognitive and behavioral abilities

Exclusion Criteria:

* age less than 50 years old
* individuals refuse to participate this study and sign the informed consent
* individuals of unclear consciousness

Primary outcomes:
measure: The correlations between measures of pulmonary function test and heart rate variability
timeFrame: 1 day test duration
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
Study officials:
affiliation: Taipei Veterans General Hospital, Taiwan
name: Diahn-Warng Perng, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00157872: A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)
Official title: A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Rheumatoid Arthritis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.


Eligibility criteria: Inclusion Criteria:

* Chinese males or females at least 18 years of age with rheumatoid arthritis

Primary outcomes:
measure: Tender joint count
measure: swollen joint count
measure: patient's global assessment of disease activity
measure: investigator's global assessment of disease activity
Secondary outcomes:
measure: Patient pain assessment
measure: patient's global assessment of response to therapy
measure: investigator's global assessment of response to therapy
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References: